HPC 250 mg/ml (IM Injection)
1 ml ampoule: ৳ 400.00 (2's pack: ৳ 800.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Hydroxyprogesterone caproate |
| Company | Popular pharmaceuticals ltd |
| Also available as |
Indications
- Reducing the risk of preterm birth in women with a singleton pregnancy
- Prevention of preterm labor in a singleton pregnancy
Description
- Synthetic steroid hormone
- Similar to medroxyprogesterone acetate and megestrol acetate
- Ester derivative of 17a-hydroxyprogesterone formed from caproic acid
Pharmacology
- Plays a vital role in regulation of the female reproductive system
- Important for successful implantation of the embryo
- Acts by binding to progesterone receptors in various body parts
- Regulates gene transcription
- Has an anti-inflammatory effect
- Maintains uterine queiscence by stabilizing progesterone acting on the myometrium
Dosage & Administration
- 500 mg or 250 mg intramuscular administration once weekly
- Administration instructions for preparing and injecting the drug
- Recommended start and end gestational weeks for treatment
Contraindications
- Thrombosis or thromboembolic disorders
- Breast cancer or other hormone-sensitive cancer
- Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
- Cholestatic jaundice of pregnancy
- Liver tumors, benign or malignant, or active liver disease
- Uncontrolled hypertension
Side Effects
- Injection site reactions
- Hives
- Itching
- Nausea
- Diarrhea
- Symptoms of blood clots
- Allergic reactions
Pregnancy & Lactation
- Pregnancy Category B
- No adequate and well-controlled studies in women during first trimester
- Detectable amounts of progestins identified in breast milk
Precautions & Warnings
- Discontinue if thrombosis or thromboembolism occurs
- Consider discontinuing if allergic reactions occur
- Monitor pre-diabetic and diabetic women
- Monitor conditions affected by fluid retention
- Monitor women with history of clinical depression
- Carefully monitor women who develop jaundice or hypertension
Use in Special Populations
- Not indicated for use in pediatric patients
- Safety and efficacy not established in pediatric patients <16 years of age
- Not evaluated in women >65 years of age
- Not intended for use in postmenopausal women
- Not established in postmenopausal women
- Contraindicated in patients with liver tumors or active liver disease
- Effect on hepatic and renal impairment on pharmacokinetics not evaluated
Overdose Effects
- No adverse events associated with overdosage reported
Therapeutic Class
- Hormone preparations for other uses
Storage Conditions
- Controlled room temperature between 15°C to 30°C
- Protect from light
- Keep out of the reach of children